JPRN-UMIN000017718已完成未知
Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer - Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer
Department of Surgical Oncology, Nagoya University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2015年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Other active concomitant malignancies; other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine; pregnant women; no informed consent
研究者
相似试验
招募中
2 期
eoadjuvant FOLFIRINOX for borderline or locally advanced pancreatic cancerJPRN-jRCT1051190099Toyama Hirochika25
招募中
不适用
A trial of Neoadjuvant modified FOLFIRINOX chemotherapy for resectable pancreatic adenocarcinomaNeoplasmsKCT0004421Yonsei University Health System, Severance Hospital27
Unknown
2 期
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic CancerBorderline Resectable Pancreatic CancerNCT02717091Nagoya University50
招募中
2 期
Phase II study of modified FOLFIRINOX as neoadjuvant chemotherapy for borderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancerborderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancerJPRN-UMIN000015707Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery23
已完成
2 期
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic CancerPancreatic AdenocarcinomaNCT02749136Asan Medical Center44